A股午間公告 | 桂林三金控股孫公司獲得美國FDA藥品臨牀試驗批準
格隆匯7月29日丨1、桂林三金:公司控股孫公司寶船生物收到美國FDA(美國食品藥品監督管理局)關於同意BC007抗體注射液用於晚期實體瘤治療進行臨牀試驗的批準函。寶船生物將盡快按照FDA的要求開展上述藥物的臨牀研究。I期臨牀試驗將評估BC007的安全性、耐受性、藥代動力學特徵、免疫原性和初步抗腫瘤療效。
2、科順股份:向不特定對象發行可轉換公司債券申請獲得深交所受理。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.